Clinical trials: Split Thickness Skin Graft
- Condition Split Thickness Skin Graft
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Wounds
OxyGenesys Dissolved Oxygen Dressing; Abdominoplasty at Northwestern University
Twelve acute wounds (6 on either side of the umbilicus) will be surgically created in the lower abdominal area. One side of the umbilicus will be randomized to Oxygenesys treatment arm and the other side will be receiving a…
- Trial name
- NCT02591537
- Testing
- OxyGenesys Dissolved Oxygen Dressing
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Halyard Health
Skin Graft Scar, Split-Thickness Skin Graft (STSG)
Efficacy and Safety Evaluation of EASYEF® in Acute Wound (Split-thickness Skin Graft Donor Site)
This study is a prospective study, randomized, using control, open-label, single-center to evaluate the efficacy and safety of EASYEF® in acute wound (split-thickness skin graft donor site).
- Trial name
- NCT05335720
- Testing
- rhEGF
- Where
- Indonesia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- PT. Daewoong Infion
Wound
Juvidex (Mannose-6-Phosphate) in Accelerating the Healing of Split Thickness Skin Graft Donor Sites
The objective of this study is to compare the efficacy of two concentrations of Juvidex with placebo on the healing of split thickness skin graft donor sites
- Trial name
- NCT00664352
- Testing
- Mannose-6-Phosphate (Juvidex), Mannose-6-Phophate (Juvidex)
- Where
- United Kingdom
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Renovo
Skin Graft Complications
Study to Assess the Safety and Efficacy of DERMASEAL for the Treatment of Split-Thickness Skin Graft Donor Site Wounds
The goal of this study to determine whether the combination biologic/drug DERMASEAL will safely decrease donor wound pain after split-thickness skin graft surgery.
- Trial name
- NCT06134843
- Testing
- DERMASEAL
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Hobart W. Harris
Skin Transplantation
Post-market Clinical Follow-up Study for a CE Marked Wound Care Product (FibDex®)
FibDex® 2-2022 is a sponsored, post-marketing clinical follow-up (PMCF) study to monitor the clinical performance and safety of the CE marked product nanofibrillar cellulose (NFC) wound dressing, FibDex®, when used according to…
- Trial name
- NCT05666999
- Testing
- FibDex®, Suprathel, Aquacel Foam
- Where
- Finland
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- UPM-Kymmene Corporation